Lymphoma Service, Division of Hematologic Malignancies, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Adult BMT Service, Division of Hematologic Malignancies, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Leuk Lymphoma. 2021 Sep;62(9):2177-2183. doi: 10.1080/10428194.2021.1897806. Epub 2021 Mar 29.
Few publications exist concerning allogeneic hematopoietic cell transplant (alloHCT) outcomes in non-Japanese patients with HTLV-1-associated ATLL. We detail the patient and disease characteristics, transplant approach, and clinical outcomes in 17 patients with ATLL at our institution who underwent alloHCT. We report favorable outcomes, with 8/17 in ongoing remission, 2/17 with prolonged (>6 years) disease-free survival, and a low incidence of transplant-related mortality (2/17). These results validate the feasibility and efficacy of alloHCT in non-Japanese patients with ATLL.
关于 HTLV-1 相关 ATLL 非日本患者的异基因造血细胞移植（alloHCT）结果，目前发表的文献很少。我们详细介绍了在我们机构接受 alloHCT 的 17 例 ATLL 患者的患者和疾病特征、移植方法和临床结果。我们报告了有利的结果，17 例中有 8 例仍在缓解中，2 例无病生存时间延长（>6 年），移植相关死亡率低（2/17）。这些结果验证了 alloHCT 在非日本 ATLL 患者中的可行性和疗效。
